	US 12,343,446 B2
	Bone repair product and methods of use thereof
Thomas E. Uveges, Elkridge, MD (US); Jin-Qiang Kuang, Glenelg, MD (US); Alla Danilkovitch, Columbia, MD (US); S. Michael Sinclair, Ellicott City, MD (US); and Sandra D. Geraghty, Elkridge, MD (US)
Assigned to OSIRIS THERAPEUTICS, INC.
Filed by OSIRIS THERAPEUTICS, INC., Columbia, MD (US)
Filed on Mar. 18, 2022, as Appl. No. 17/698,602.
Application 15/298,142 is a division of application No. 14/849,509, filed on Sep. 9, 2015, granted, now 10,729,809, issued on Aug. 4, 2020.
Application 17/698,602 is a continuation of application No. 17/039,402, filed on Sep. 30, 2020, abandoned.
Application 17/039,402 is a continuation of application No. 15/298,142, filed on Oct. 19, 2016, granted, now 10,828,395.
Claims priority of provisional application 62/053,063, filed on Sep. 19, 2014.
Prior Publication US 2022/0202991 A1, Jun. 30, 2022
Int. Cl. A61K 38/18 (2006.01); A61L 27/36 (2006.01); A61L 27/38 (2006.01); A61L 27/40 (2006.01); A61L 27/54 (2006.01); A61P 19/08 (2006.01)

CPC A61L 27/3608 (2013.01) [A61K 38/18 (2013.01); A61K 38/1825 (2013.01); A61K 38/1841 (2013.01); A61K 38/1866 (2013.01); A61L 27/3604 (2013.01); A61L 27/365 (2013.01); A61L 27/3683 (2013.01); A61L 27/3687 (2013.01); A61L 27/3691 (2013.01); A61L 27/3821 (2013.01); A61L 27/3834 (2013.01); A61L 27/3847 (2013.01); A61L 27/40 (2013.01); A61L 27/54 (2013.01); A61P 19/08 (2018.01); A61L 2300/414 (2013.01); A61L 2300/64 (2013.01); A61L 2430/02 (2013.01); A61L 2430/40 (2013.01)]

25 Claims

1. A method of repairing a bone defect, the method comprising administering to the site of the bone defect a bone repair composition comprising:

(a) cancellous bone chips comprising viable cells, wherein the cancellous bone chips are not processed with a loosening agent,

(b) 5-20 wt. % devitalized and non-immunogenic periosteum pieces, based on the total weight of the composition, and

wherein one or more growth factors comprised in the composition promote angiogenesis at the site of the bone defect.